![]() |
|
|
|||||||
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
All amounts are in U.S. dollars QUEBEC CITY, March 24 /PRNewswire-FirstCall/ - Ãterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009 . 2009 Highlights Perifosine - Updated positive ...
|
| Thread Tools | |
| Display Modes | |
|
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Molecular Insight Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial | cancerfr | Pheochromocytoma | 0 | 04-01-2010 04:05 AM |
| Æterna Zentaris announces 2009 financial and operating results (News-Medical-Net) | cancerfr | Adrenocortical Carcinoma | 0 | 03-24-2010 03:38 PM |
| Æterna Zentaris announces 2009 financial and operating results (News-Medical-Net) | cancerfr | Endometrial Cancer | 0 | 03-24-2010 03:38 PM |
| MDRNA, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results (Marketwire | cancerfr | Adrenocortical Carcinoma | 0 | 03-23-2010 08:16 PM |
| MDRNA, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results (Marketwire | cancerfr | Bladder Cancer | 0 | 03-23-2010 08:16 PM |